Across TCGA pan-cancer cohorts, MAPK11 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MAPK11 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MAPK11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPK11 expression acts as an unfavorable survival marker.
BLCA, BRCA, and HNSC are the cancer types where MAPK11 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.